Neuropsychiatric manifestations and sleep disturbances in children and adolescents randomised to dolutegravir-based ART vs standard-of-care in the ODYSSEY trial
29 Jul, 2021
Authors: Violari A, Kekitiinwa A, White E, Mumbiro V, Rutebarika D, Dobbels E, Kataike H, Moloantoa T, Atwine L, Nazzinda R, Mbabazi R, Kanjanavanit S, Mosia N, Na-Rajsimax S, Techakunakorn…
Read MoreEffect of dolutegravir on folate and vitamin B12 status among HIV- infected children and adolescents in the ODYSSEY trial
29 Jul, 2021
Authors: L. Barlow-Mosha, G. Ahimbisibwe, E. Chappell, P.M. Amuge, A. Nanduudu, E. Kaudha, T. Amukele, D. Balamusani, B. Kafufu, A. Nimwesiga, C. Kityo, A.R Kekitiinwa, R. Namwanje, G. Kasangaki, A.…
Read MoreDolutegravir-Based ART is Superior to Standard of Care in Young Children Living With HIV
29 Jul, 2021
Authors: P Amuge on behalf of the ODYSSEY trial team Published in: International workshop on HIV pediatrics 2021 Abstract Background: ODYSSEY, a multi-country randomised trial, demonstrated superior treatment efficacy…
Read MoreWeight Gain in Children and Adolescents on Dolutegravir vs Standard-of-Care in the ODYSSEY Trial
29 Jul, 2021
Authors: Mujuru H , Lugemwa A, Puthanakit T, Amuge P, Kityo C, Compagnucci A, Variava E, Kekitiinwa A, Musiime V, BarlowMosha L, Ngampiyaskul C, Zuidewind P, Tumusiime J, Mngqbisa R,…
Read MoreA randomised comparison of DTG-based ART vs Standard of Care in infants and young children living with HIV weighing 3 to 14kg: results from the ODYSSEY trial
29 Jul, 2021
Authors: A Lugemwa, H Mujuru, B Wynne, A Violari, AR Kekitiinwa, CM Kity, M Archary, E Variava, T Sarfati, C Shakeshaft, R Turner, K Nathoo, E Chidziva, L Atwine, N…
Read MoreVirological failures and genotypic resistance in children and adolescents randomised to dolutegravir-based ART vs. standard-of-care in the ODYSSEY trial
29 Jul, 2021
Authors: C. Kityo, E. White, A. Turkova, H.A Mujuru, I. Nankya, B. Wynne, S. Ali, A. Kekitiinwa, A. Lugemwa, E. Kaudha, A. Liberty, H. Cassim, M. Archary, M. Cotton, L.…
Read MoreA randomised comparison of DTG-based ART vs Standard of Care in infants and young children living with HIV weighing 3 to 14kg: results from the ODYSSEY trial
21 Jul, 2021
Authors: LugemwaA, Mujuru H, Wynne B, Violari A, Kekitiinwa R.A, Kityo M.C, Archary M, Variava E, Sarfati T, Shakeshaft C, Turner R, Nathoo R, Chidziva E, Atwine L, Ramsagar N, Liberty…
Read MoreNeuropsychiatric manifestations and sleep disturbances in children and adolescents randomised to dolutegravir-based ART vs standard-of-care in the ODYSSEY trial
21 Jul, 2021
Authors: Turkova A, Kekitiinwa A, White E, Mumbiro V, Khauda E, Liberty A, Dobbels E, Ahimbisibwe M.G, Moloantoa T, Atwine T, Kanjanavanit S, Mosia R.N, Puthanakit T, Smit T, Kobbe R,…
Read MoreWeight gain in children and adolescents on dolutegravir vs standard of care in the ODYSSEY trial
21 Jul, 2021
Authors: Turkova A, Kityo C, Mujuru A.H, Variava E, Kekitiinwa A, Lugemwa A, Barlow-Mosha L, Ngampiyaskul C, Zuidewind P, Puthanakit T, Mngqbisa R, Behuhuma O.N, Kataike H, Musoro G, Nandudu A,…
Read MoreVirological failures and genotypic resistance in children and adolescents randomised to dolutegravir-based ART vs. standard-of-care in the ODYSSEY trial
21 Jul, 2021
Authors: Kityo C, White E, Turkova A, Mujuru A.H, Nankya I, Wynne B, Ali S, Kekitiinwa A, Lugemwa A, Kaudha E, Liberty A, Cassim H, Archary M, Cotton M, Barlow-Mosha L,…
Read MoreOnce daily integrase inhibitor (INSTI) with boosted darunavir is non-inferior to standard of care in virologically suppressed children – Week 48 results of the SMILE Penta-17 Trial
19 Jul, 2021
Authors: Compagnucci A, Chan M, Saïdi Y, Cressey T, Bamford A, Riault Y, Coelho A, Nolan A, Chalermpantmetagul S, Amuge P, Musiime V, Violari A, Cotton M, Kekitiinwa A, Kaudha…
Read MoreOnce-Daily Integrase Inhibitor (Insti) With Boosted Darunavir is Non- Inferior to Standard of Care in Virogically Suppressed Children, Week 48 Results of the SMILE PENTA-17 Trial
19 Jul, 2021
Authors: Compagnucci A , Chan M , Saïdi Y , Cressey T , Bamford A , Riault Y , Coelho A , Nolan A ,Chalermpantmetagul S , Amuge P ,…
Read MoreBecause we all have to grow up”: supporting adolescents in Uganda to develop core competencies to transition towards managing their HIV more independently
22 Mar, 2021
Authors: Chloe Lanyon, Janet Seeley, Stella Namukwaya, Victor Musiime, Sara Paparini, Helen Nakyambadde, Christine Matama, Anna Turkova, Sarah Bernays Published in: Journal of International Aids Society Abstract Introduction: Sustaining optimal adherence is the major challenge facing adolescents…
Read MoreDOLUTEGRAVIR-BASED ART IS SUPERIOR TO NNRTI/PI- BASED ART IN CHILDREN AND ADOLESCENTS
11 Mar, 2021
Authors: Anna Turkova1, for the ODYSSEY/PENTA-20 Trial Team Published in: CROI 2021 Abstract: ODYSSEY is an international multi-centre randomised non-inferiority trial evaluating dolutegravir (DTG) + 2NRTIs versus standard-of-care (SOC)…
Read MoreODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing
19 Feb, 2021
Authors: Cecilia L. Moore, Anna Turkova , Hilda Mujuru , Adeodata Kekitiinwa, Abbas Lugemwa, Cissy M. Kityo, Linda N. Barlow-Mosha, et al, ODYSSEY trial team Published in: BMC Infectious Diseases…
Read MorePediatric dolutegravir (DTG) dosing recommendations derived from combined P1093 and ODYSSEY Population Pharmacokinetic analysis
04 Dec, 2020
Authors: Singh R, Baker M, Thapar M, Gibb D, Turkova A, Ford D, Ruel T, Wiznia A, Farhad M, Alvero C, Green J, Bollen P, Colbers A, Burger D, Acosta…
Read MoreSimplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trial
06 Aug, 2020
Authors: Bollen P, Moore CL , Mujuru H et al; the ODYSSEY trial team Published in: LANCET HIV. 2020;8:e533-e544 Background Paediatric dolutegravir doses approved by stringent regulatory authorities (SRAs) for…
Read MoreAdeqaute dolutegravir exposure dosed BID with rifampicin in children 6 to < 18 years
13 Mar, 2020
Authors: Waalewijn H, Mujuru HA, Amuge P, Cotton M, Bollen P, Chan M, Ali S, Variavan E, Makumbi S, Colbers A, Gibb D, Ford D, Burger D, Turkova A, and…
Read More